ERBB2 and breast carcinoma: For example, patients with BCR-ABL leukemias, HER2-overexpressing breast cancers, or EGFR-driven lung cancers benefit immensely from kinase-targeted therapies (often as adjuvants to chemotherapy, radiation, and/or surgery).